Patients on hemodialysis (HD; n = 210) were examined for peripheral arterial disease (PAD) using ankle-brachial index (ABI) and toe-brachial index (TBI). The prevalence of PAD was 38.1%. Among patients with PAD, 87.5% were newly diagnosed with PAD, 42.5% were diagnosed with TBI <0.6 despite ABI ≥ 0.9, and 68.7% had no lower limb symptoms. In patients with PAD, the prevalence rate of cerebrovascular disease was 36.3%, coronary artery disease was 42.5%, spinal stenosis was 33.2%, and vertebral fracture 15.0% and was significantly higher than those of the non-PAD patients. Low high-density lipoprotein cholesterol was the most important biomarker among patients with PAD. PAD has been underdiagnosed and untreated in patients on HD because most patients do not have symptoms that could be due to diabetic neuropathy or have insufficient daily activity to experience exertional leg symptoms. Screening for PAD using the ABI and TBI increased diagnostic efficiency in patients on HD and may lead to effective early treatments, including pharmacotherapy, revascularization therapy, and exercise rehabilitation to avoid the worst possible scenario such as lower limb amputation, cardiovascular event, and death.
SarnakMJLeveyASSchoolwerthAC. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154–2169.
2.
SelvinEErlingerTP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004;110(6):738–743.
3.
O'HareAJohansenK. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol. 2001;12(12):2838–2847.
4.
RajagopalanSDellegrottaglieSFurnissAL. Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Circulation. 2006;114(18):1914–1922.
5.
StegPGBhattDLWilsonPW. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11):1197–1206.
6.
McDermottMMGreenlandPLiuK. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA. 2001;286(13):1599–1606.
7.
SieminskiDJGardnerAW. The relationship between free-living daily physical activity and the severity of peripheral arterial occlusive disease. Vasc Med. 1997;2(4):286–291.
8.
RegensteinerJGHiattWRCollJR. The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program. Vasc Med. 2008;13(1):15–24.
9.
CriquiMHLangerRDFronekA. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326(6):381–386.
10.
OnoKTsuchidaAKawaiH. Ankle-brachial blood pressure index predicts all-cause and cardiovascular mortality in hemodialysis patients. J Am Soc Nephrol. 2003;14(6):1591–1598.
11.
CriquiMHDenenbergJOBirdCEFronekAKlauberMRLangerRD. The correlation between symptoms and non-invasive test results in patients referred for peripheral arterial disease testing. Vasc Med. 1996;1(1):65–71.
12.
DiehmCAllenbergJRPittrowD. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120(21):2053–2061.
13.
Al-ThaniHEl-MenyarAKoshyV. Implications of foot ulceration in hemodialysis patients: a 5-year observational study. J Diabetes Res. 2014;2014:945075.
14.
ChuaHRLauTLuoN. Predicting first-year mortality in incident dialysis patients with end-stage renal disease - the UREA5 study. Blood purif. 2014;37(2):85–92.
15.
BelchJJTopolEJAgnelliG. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med. 2003;163(8):884–892.
16.
IshiiHKumadaYTakahashiH. Impact of diabetes and glycaemic control on peripheral artery disease in Japanese patients with end-stage renal disease: long-term follow-up study from the beginning of haemodialysis. Diabetologia. 2012;55(5):1304–1309.
17.
JonesNJChessJCawleySPhillipsAORileySG. Prevalence of risk factors for foot ulceration in a general haemodialysis population. Int Wound J. 2012;10(6):683–688.
18.
HuLSekineMGainaAWangHKagamimoriS. Nested case-control study on associations between lung function, smoking and mortality in Japanese population. Environ Health Prev Med. 2007;12(6):265–271.
19.
McDermottMMMehtaSGreenlandP. Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease. Arch Intern Med. 1999;159(4):387–392.
20.
OkamotoKOkaMMaesatoK. Peripheral arterial occlusive disease is more prevalent in patients with hemodialysis: comparison with the findings of multidetector-row computed tomography. Am J Kidney Dis. 2006;48(2):269–276.
21.
SuominenVRantanenTVenermoMSaarinenJSaleniusJ. Prevalence and risk factors of PAD among patients with elevated ABI. Eur J Vasc Endovasc Surg. 2008;35(6):709–714.
22.
LeskinenYSaleniusJPLehtimakiTHuhtalaHSahaH. The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis. 2002;40(3):472–479.
23.
DoobayAVAnandSS. Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review. Arterioscler Thromb Vasc Biol. 2005;25(7):1463–1469.
24.
GolombBADangTTCriquiMH. Peripheral arterial disease: morbidity and mortality implications. Circulation. 2006;114(7):688–699.
25.
OhtakeTOkaMIkeeR. Impact of lower limbs' arterial calcification on the prevalence and severity of PAD in patients on hemodialysis. J Vasc Surg. 2011;53(3):676–683.
26.
TsuyukiKKohnoKEbineK. Exercise-ankle brachial pressure index with one-minute treadmill walking in patients on maintenance hemodialysis. Ann Vasc Dis. 2013;6(1):52–56.
27.
JohansenKLChertowGMNgAV. Physical activity levels in patients on hemodialysis and healthy sedentary controls. Kidney Int. 2000;57(6):2564–2570.
28.
ZamojskaSSzklarekMNiewodniczyMNowickiM. Correlates of habitual physical activity in chronic haemodialysis patients. Nephrol Dial Transplant. 2006;21(5):1323–1327.
29.
MatsuzawaRMatsunagaAWangG. Habitual physical activity measured by accelerometer and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2012;7(12):2010–2016.
30.
KutsunaTMatsunagaAMatsumotoT. Physical activity is necessary to prevent deterioration of the walking ability of patients undergoing maintenance hemodialysis. Ther Apher Dial. 2010;14(2):193–200.
31.
NakaiSIsekiKItamiN. An overview of regular dialysis treatment in Japan (as of 31 December 2010). Ther Apher Dial. 2012;16(6):483–521.
32.
NdipARutterMKVileikyteL. Dialysis treatment is an independent risk factor for foot ulceration in patients with diabetes and stage 4 or 5 chronic kidney disease. Diabetes Care. 2010;33(8):1811–1816.
33.
StamboulisEVoumvourakiKZambelisT. There is No Association between Cardiovascular Autonomic Dysfunction and Peripheral Neuropathy in Chronic Hemodialysis Patients. J Clin Neurol. 2010;6(3):143–147.
34.
McDermottMMGuralnikJMFerrucciL. Asymptomatic peripheral arterial disease is associated with more adverse lower extremity characteristics than intermittent claudication. Circulation. 2008;117(19):2484–2491.
35.
LinJSOlsonCMJohnsonESWhitlockEP. The ankle-brachial index for peripheral artery disease screening and cardiovascular disease prediction among asymptomatic adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;159(5):333–341.
36.
BenetosAZureikMMorcetJ. A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men. J Am Coll Cardiol. 2000;35(3):673–680.
37.
Kalantar-ZadehKStrejaEKovesdyCP. The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc. 2010;85(11):991–1001.
38.
DrechslerCKraneVRitzEMarzWWannerC. Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation. 2009;120(24):2421–2428.
39.
ShojiTMasakaneIWatanabeYIsekiKTsubakiharaY. Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol. 2011;6(5):1112–1120.
40.
HirakataHNittaKInabaM. Japanese Society for Dialysis Therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis. Ther Apher Dial. 2012;16(5):387–435.
41.
YamazakiTGotoSShigematsuH. Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan. Circ J. 2007;71(7):995–1003.
42.
GoldbergAPGeltmanEMHagbergJM. Therapeutic benefits of exercise training for hemodialysis patients. Kidney Int Suppl. 1983;16:S303–S309.
43.
MatsuzawaRMatsunagaAKutsunaT. Association of habitual physical activity measured by an accelerometer with high-density lipoprotein cholesterol levels in maintenance hemodialysis patients. ScientificWorldJournal. 2013;2013:780783.
